30 44

Cited 0 times in

Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis

Authors
 Doo Yong Chung  ;  Dong Hyuk Kang  ;  Jong Won Kim  ;  Do Kyung Kim  ;  Joo Yong Lee  ;  Chang Hee Hong  ;  Kang Su Cho 
Citation
 CANCERS, Vol.11(12) : E1830, 2019 
Journal Title
 CANCERS 
Issue Date
2019
Keywords
adverse events ; alternative dosing ; meta-analysis ; renal cell carcinoma ; sunitinib ; survival outcomes ; systematic review
Abstract
Treatment-related adverse events (AEs) can obfuscate the maintenance of a conventional schedule of sunitinib in patients with metastatic renal cell carcinoma. Accordingly, alternative schedules seeking to improve the safety profile of sunitinib have been tested. Recently, two meta-analyses similarly described improved safety profiles favoring a two weeks on and one week off (2/1) schedule, but with conflicting results for survival outcomes. Therefore, we conducted an updated systematic review and meta-analysis, including all recently published studies and using complementary statistical methods. Endpoints included progression-free survival, overall survival, and AEs of 15 types. Eleven articles were included in this meta-analysis. Using adjusted findings, we noted statistically better results in progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.39-0.84; p = 0.005), but no difference in overall survival (hazard ratio, 0.66; 95% confidence interval, 0.42-1.04; p = 0.08). Moreover, the 2/1 schedule was beneficial for reducing the incidence of several AEs. Conclusively, our meta-analysis suggests that the 2/1 schedule holds promise as an alternative means of reducing AEs and maintaining patient quality of life. While the survival outcomes of the 2/1 schedule seem also to be favorable, the level of evidence for this was low, and the interpretation of these findings should warrant caution. Large scale randomized trials are needed to support these results.
Files in This Item:
T201904900.pdf Download
DOI
10.3390/cancers11121830
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jong Won(김종원) ORCID logo https://orcid.org/0000-0002-0449-228X
Lee, Joo Yong(이주용) ORCID logo https://orcid.org/0000-0002-3470-1767
Cho, Kang Su(조강수) ORCID logo https://orcid.org/0000-0002-3500-8833
Hong, Chang Hee(홍창희) ORCID logo https://orcid.org/0000-0002-0946-7702
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/174577
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse